Clinical trial
Augmentation of Parasympathetic Signaling With Pyridostigmine in Heart Failure
NCT01415921 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Augmentation of Parasympathetic Signaling With Pyridostigmine in Heart Failure
- Lead sponsor
- NYU Langone Health
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2011
- Completion date
- July 31, 2015
- Enrollment
- 33 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.